Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: Montana Wildhack who wrote (8127)	11/29/2001 11:18:48 AM
From: twentyfirstcenturyfox	Read Replies (2) \| Respond to of 14101

Wolf: it is interesting that the only regular source of actual figures for Pennsaid sales is coming from Provalis. Seems to be only £20,000 sales in the four months of July/October 2001 (£5,000 per month) on top of £100,000 (referred to in Provalis annual report) for the first three months of the launch months of April/June 2001(£33,000 per month), total £120,000 sterling for the seven months to end October (announced at the AGM on 26 November). Sales per month are down over the months of July/October but the earlier months could have involved some stocking of Pennsaid by pharmacies. Sales could be better! Difficult to know if these poor sales (below expectations) is due to ineffective marketing/selling by Provalis or resistance to acceptance of the product or just very conservative medics etc. At this rate of UK sales, it is not surprising that DMX reported no sales for its recent first fiscal quarter. Provalis must still be selling from its first shipment of Pennsaid from Canada. Otherwise, excellent moves by management - can not wait until they find a similar fast moving marketer for the rest of EU. Fox.